Caris Life Sciences, Inc. splits its revenue into 2 lines in its filings. The largest line in Q3 of fiscal 2026, the quarter ended Sep 30, 2026 was Molecular Profiling Services at $262.7 million, 95% of the total.
USD in millions. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Sep 30, 2026
|
Q3 FY2026
Sep 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
|---|---|---|---|---|---|---|---|
| Revenue |
1,048
|
275
|
264
|
216
|
293
|
217
|
181
|
| Molecular Profiling Services |
1,008
+74.1%
share 96.2%
|
263
+26.6%
share 95.4%
|
252
+54.8%
share 95.7%
|
211
share 97.5%
|
282
share 96.3%
|
208
share 95.7%
|
163
share 89.8%
|
| Pharma Research And Development Services |
40
-42.5%
share 3.8%
|
13
+36.8%
share 4.6%
|
11
-38.0%
share 4.3%
|
5
share 2.5%
|
11
share 3.7%
|
9
share 4.3%
|
18
share 10.2%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.
Company profile
- Industry
- Services-Medical Laboratories (SIC 8071)
- Listed as
- CAI (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- TX
- Headquarters
- Irving, TX
- SEC filer status
- Non-accelerated filer, Emerging growth company
- SEC CIK
- 2019410
Other Services-Medical Laboratories companies
- Natera, Inc. NTRA
- Labcorp Holdings Inc. LH
- Quest Diagnostics Inc DGX
- Guardant Health, Inc. GH
- GRAIL, Inc. GRAL
- RadNet, Inc. RDNT
- BillionToOne, Inc. BLLN
- CareDx, Inc. CDNA
Source: SEC EDGAR filings. This is company-reported data, not investment advice.